Repligen price target raised to $180 from $145 at Canaccord
Canaccord raised the firm’s price target on Repligen (RGEN) to $180 from $145 and keeps a Hold rating on the shares. The firm updated its model ahead of Q3 results.
Fiscal Year: January - December
Repligen Corporation (RGEN), listed on the NASDAQ, has a market capitalization of $9.99B. As of Oct 24, 2026, the stock is trading at $176.93 per share@else an unavailable price , offering investors a clear view of its current market value. Repligen Corporation is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 242.44, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Repligen Corporation also offers a dividend yield of N/A , making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that Repligen Corporation (RGEN) has a DCF fair value that is only shown to premium members. To see it, please Login or Upgrade for access.
The proprietary SS Score for Repligen Corporation is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Repligen Corporation, Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Repligen Corporation is 89.18, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Repligen Corporation (RGEN) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Repligen Corporation (RGEN) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. It is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Repligen Corporation (RGEN) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Repligen Corporation. To access the full SS Score, consider upgrading your subscription.
Repligen Corporation is a significant player in the industry sector, with a market capitalization of $9.99B and a competitive P/E ratio of 242.44. Investors should compare these metrics with industry peers to gauge whether Repligen Corporation is outperforming or underperforming within its sector.
Canaccord raised the firm’s price target on Repligen (RGEN) to $180 from $145 and keeps a Hold rating on the shares. The firm updated its model ahead of Q3 results.
WALTHAM, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), today announced that the Company will report its third quarter 2026 financial results on Tuesday, October 27, 2026...
Barclays analyst Luke Sergott raised the firm’s price target on Repligen (RGEN) to $225 from $175 and keeps an Overweight rating on the shares. The firm adjusted targets in the…
WALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN, “Repligen”, or the “Company”), a life sciences company focused on bioprocessing technology leadership, today annou...
Repligen (RGEN) is acquiring BioLife Solutions (BLFS) in a deal expected to be completed soon, pending final closing conditions.
UBS assumed coverage of Repligen (RGEN) with a Buy rating and $225 price target Repligen is a differentiated pure-play bioprocessing growth story with a path to sustained mid-teens revenue growth…
WALTHAM, Mass., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate i...
Stifel views Moderna’s (MRNA) Phase 3 INTerpath-001 data as good for Repligen (RGEN) and “conceptually good” for Maravai Lifesciences (MRVI). Repligen called out specific involvement in Moderna and Me...
Wells Fargo notes that Merck (MRK) and Moderna (MRNA) announced interim Phase 3 data for the latter’s personalized cancer vaccine, which hit their primary endpoint. While hard to quantify at…
Shares in Biopharma manufacturing company Repligen Corporation ($RGEN) raced 3% higher in early trading today after blockbuster results and a top analyst declaring it a market leader. Stellar Q2 Resul...
JPMorgan raised the firm’s price target on Repligen (RGEN) to $175 from $165 and keeps an Overweight rating on the shares.
Reports Q2 revenue $204.13M, consensus $201.4M. Olivier Loeillot, President and Chief Executive Officer of Repligen (RGEN) said, “We were very pleased to deliver 13% organic growth in the second quart...
Raises FY26 revenue view to $813M-$835M from $803M-$833M, consensus $821.04M. The company said, “Our financial guidance for the full year 2026 is based on expectations for our existing business. Our…
WALTHAM, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its s...
BioLife Solutions, a Bothell, Wash.-based company developing tools for cell and gene therapy, is being acquired for $1.5 billion by the life sciences corporation Repligen.
Lake Street downgraded BioLife Solutions (BLFS) to Hold from Buy with a price target of $31, down from $33, after Repligen (RGEN) announced a definitive agreement to acquire the company…
Projected from reported cash flow (SEC filings). The starting point is the latest yearly revenue times the median free cash flow margin of the last five years. Years 1 to 5 grow at the revenue growth rate of the last five years (between -5% and 15%), and years 6 to 10 slow down to the 2.5% perpetual growth rate. These are Studying Stocks' own estimates, not analyst forecasts, and are intended for educational purposes only as a baseline for the analysis.
| Year | FCF Estimate | % | Source |
|---|---|---|---|
| 2026 | 92.92M | 2.43% | Projected |
| 2027 | 95.18M | 2.43% | Projected |
| 2028 | 97.49M | 2.43% | Projected |
| 2029 | 99.87M | 2.43% | Projected |
| 2030 | 102.30M | 2.43% | Projected |
| 2031 | 104.80M | 2.45% | Projected |
| 2032 | 107.38M | 2.46% | Projected |
| 2033 | 110.04M | 2.47% | Projected |
| 2034 | 112.78M | 2.49% | Projected |
| 2035 | 115.59M | 2.50% | Projected |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
| Year | FCF | Discount Factor | PV of Future FCF |
|---|---|---|---|
| 2024A | 149.72M | 1.00 | 149.72M |
| 2025A | 93.90M | 1.00 | 93.90M |
| 2026E | 92.92M | 1.09 | Login |
| 2027E | 95.18M | 1.19 | Login |
| 2028E | 97.49M | 1.29 | Login |
| 2029E | 99.87M | 1.41 | Login |
| 2030E | 102.30M | 1.53 | Login |
| 2031E | 104.80M | 1.67 | Login |
| 2032E | 107.38M | 1.82 | Login |
| 2033E | 110.04M | 1.98 | Login |
| 2034E | 112.78M | 2.16 | Login |
| 2035E | 115.59M | 2.35 | Login |
| Terminal | 2.35 | Login |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.